558 related articles for article (PubMed ID: 19267726)
1. The role of amifostine in the treatment of head and neck cancer with cisplatin-radiotherapy.
Marcu LG
Eur J Cancer Care (Engl); 2009 Mar; 18(2):116-23. PubMed ID: 19267726
[TBL] [Abstract][Full Text] [Related]
2. [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors].
Altmann S; Hoffmanns H
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():30-3. PubMed ID: 10584138
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection?
Vacha P; Fehlauer F; Mahlmann B; Marx M; Hinke A; Sommer K; Richter E; Feyerabend T
Strahlenther Onkol; 2003 Jun; 179(6):385-9. PubMed ID: 12789464
[TBL] [Abstract][Full Text] [Related]
4. Potential for use of amifostine in cervical cancer.
Small W
Semin Oncol; 2002 Dec; 29(6 Suppl 19):34-7. PubMed ID: 12577241
[TBL] [Abstract][Full Text] [Related]
5. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients.
Rades D; Fehlauer F; Bajrovic A; Mahlmann B; Richter E; Alberti W
Radiother Oncol; 2004 Mar; 70(3):261-4. PubMed ID: 15064010
[TBL] [Abstract][Full Text] [Related]
6. The potential role of amifostine in conjunction with cisplatin in the treatment of locally advanced carcinoma of the cervix.
Wadler S; Goldberg G; Fields A; Anderson P; Beitler JJ; Sood B; Haynes H; Runowicz C
Semin Oncol; 1996 Aug; 23(4 Suppl 8):64-8. PubMed ID: 8783670
[TBL] [Abstract][Full Text] [Related]
7. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study.
Buentzel J; Micke O; Adamietz IA; Monnier A; Glatzel M; de Vries A
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):684-91. PubMed ID: 16243440
[TBL] [Abstract][Full Text] [Related]
8. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501).
Bernier J; Cooper JS; Pajak TF; van Glabbeke M; Bourhis J; Forastiere A; Ozsahin EM; Jacobs JR; Jassem J; Ang KK; Lefèbvre JL
Head Neck; 2005 Oct; 27(10):843-50. PubMed ID: 16161069
[TBL] [Abstract][Full Text] [Related]
9. Amifostine and curative intent chemoradiation for compromised cancer patients.
Nguyen NP; Levinson B; Dutta S; Karlsson U; Kelly KC; Dowell J; Ludin A; Sallah S
Anticancer Res; 2003; 23(2C):1649-56. PubMed ID: 12820436
[TBL] [Abstract][Full Text] [Related]
10. Stochastic modelling of the role of cisplatin in altered fractionation schedules for head and neck cancer.
Marcu L; Bezak E
Phys Med; 2010 Oct; 26(4):177-83. PubMed ID: 20034829
[TBL] [Abstract][Full Text] [Related]
11. Head and neck squamous cell carcinoma: optimizing the therapeutic index.
Rosenthal DI; Blanco AI
Expert Rev Anticancer Ther; 2005 Jun; 5(3):501-14. PubMed ID: 16001957
[TBL] [Abstract][Full Text] [Related]
12. Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721).
Kurbacher CM; Mallmann PK
Anticancer Res; 1998; 18(3C):2203-10. PubMed ID: 9703784
[TBL] [Abstract][Full Text] [Related]
13. Effect of Amifostine to prevent radiotherapy-induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function.
Veerasarn V; Phromratanapongse P; Suntornpong N; Lorvidhaya V; Sukthomya V; Chitapanarux I; Tesavibul C; Swangsilpa T; Khorprasert C; Shotelersuk K; Kongthanarat Y; Panichevaluk A; Chiewvit S; Pusuwan P; Aekmahachai M; Ratchadara S; Sirilipoche S; Saengsuda Y
J Med Assoc Thai; 2006 Dec; 89(12):2056-67. PubMed ID: 17214057
[TBL] [Abstract][Full Text] [Related]
14. Amifostine reduces radiation therapy-induced dry mouth in head and neck cancer patients.
Oncology (Williston Park); 2004 Sep; 18(10):1314, 1316. PubMed ID: 15526835
[No Abstract] [Full Text] [Related]
15. A new administration schedule for amifostine as a radioprotector in cancer therapy.
Wagner W; Radmard A; Schönekaes KG
Anticancer Res; 1999; 19(3B):2281-3. PubMed ID: 10472344
[TBL] [Abstract][Full Text] [Related]
16. The potential of amifostine: from cytoprotectant to therapeutic agent.
Santini V; Giles FJ
Haematologica; 1999 Nov; 84(11):1035-42. PubMed ID: 10553165
[TBL] [Abstract][Full Text] [Related]
17. Scheduling cisplatin and radiotherapy in the treatment of squamous cell carcinomas of the head and neck: a modelling approach.
Marcu L; Bezak E; Olver I
Phys Med Biol; 2006 Aug; 51(15):3625-37. PubMed ID: 16861770
[TBL] [Abstract][Full Text] [Related]
18. Influence of amifostine on late radiation-toxicity in head and neck cancer--a follow-up study.
Büntzel J; Glatzel M; Mücke R; Micke O; Bruns F
Anticancer Res; 2007; 27(4A):1953-6. PubMed ID: 17649803
[TBL] [Abstract][Full Text] [Related]
19. A randomized phase II trial of amifostine for head and neck irradiation in lymphoma.
Ng AK; Hickey G; Li S; Neuberg D; Mauch PM
Semin Oncol; 2004 Dec; 31(6 Suppl 18):20-4. PubMed ID: 15726518
[TBL] [Abstract][Full Text] [Related]
20. Chemoradiotherapy for head and neck cancer: 'local' side effects are actually systemic.
J Support Oncol; 2006 Feb; 4(2):88. PubMed ID: 16499131
[No Abstract] [Full Text] [Related]
[Next] [New Search]
